Introduction
============

Body mass index (BMI) is the most widely used measurement of adiposity, which is an established risk factor for various diseases, including type 2 diabetes, cardiovascular disease, metabolic disturbances, and cancers [@B1]-[@B3]. High BMI (25 kg/m^2^ or greater), including overweight and obesity, contribute to cancer incidence and death across a broad range of cancers [@B4],[@B5]. High BMI affects the majority of the adult population in most developed countries, and its prevalence is increasing rapidly in developing countries. If the current worldwide trends continue, the number of people with obesity will reach nearly 2.0 billion by 2025 [@B6]. In addition, the prevalence of cancer has increased in parallel with obesity [@B7]. In the period between 1982 and 2012, a quarter of the cancer cases could be attributed to high BMI [@B8]. Overall, high BMI is likely one of the drivers for the increasing incidences of cancer.

Numerous genome-wide association studies between single nucleotide polymorphisms (SNPs) and BMI have allowed for a better understanding of the biological basis of high BMI resulting in diseases ^9,10.^ A study on pancreatic cancer found that the inflammatory NF-κB-mediated chemokine signaling pathway was associated with obesity, and contribute to a risk for pancreatic cancer [@B11]. Another study revealed that 7 BMI-associated SNPs located in 8 obesity-related genes were significantly associated with a risk for endometrial cancer [@B12]. Similarly, SNPs in genes known to be associated with metabolism and obesity are relevant to prostate cancer [@B13]. These findings suggest that high BMI associated with multiple genes and can influence various biological pathways, thus contributing to the susceptibility of complex human cancers.

Further advances in genomic technologies have brought epigenome-wide association studies (EWAS) to focus on improving the understanding of epigenetic alterations that are associated with diseases [@B14]. DNA methylation modulation, a well-known and critical regulation level of epigenetic machinery, is easily susceptible to environmental factors [@B15]-[@B17]. Unlike stable and conserved genetic variants, epigenetic processes are highly dynamic during an individual\'s lifetime, which has attracted much attention to the study of DNA methylation [@B18]. Increasing evidences for DNA methylation sites in relation to high BMI support the hypothesis that altered DNA methylation of metabolically important genes are mediated by adiposity in human blood [@B3],[@B19],[@B20]. Moreover, alterations in DNA methylation are consequences of adiposity rather than the trigger [@B3].

Changes in DNA methylation can indeed be implicated in the initiation and progression of neoplasm [@B21]. *Sirtuin 1*, a gene related to epigenetic silencing, links obesity to cancer, and also plays a role in colorectal cancer development, suggesting that obesity-related epigenetic changes may be an important determinant in colorectal cancer [@B22]. DNA methylation patterns that link high BMI to cancer development appear to be predictable, however, they are not well understood. Furthermore, a previous study that analyzed 345 breast tumor samples has also shown an association between BMI and DNA methylation in tumor tissues [@B23]. The publicly available Cancer Genome Atlas (TCGA) has provided large-scale genome sequencing data alongside clinical features for over 30 human tumors, which allows researchers to systematically study possible interactions between epigenetic changes induced by high BMI and cancer risk [@B24]. In this study, we examined genome-wide DNA methylation profiles in tumor tissues to investigate whether BMI levels change and whether these changes were associated with a high BMI. Understanding the epigenetic molecular links may provide an avenue for diagnostic and therapeutic strategies.

Materials and Methods
=====================

The data from The Cancer Genome Atlas
-------------------------------------

We downloaded patients\' clinical information from the Broad GDAC Firehose (<http://gdac.broadinstitute.org/>) and selected 15 types of cancers with the patients\' weight and height information at diagnosis to estimate individual BMI values as weight in kilograms divided by the square of height in meters. These cancers include bladder urothelial carcinoma (BLCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), esophageal adenocarcinoma (EAC), esophageal squamous cell carcinoma (ESCC), kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), rectum adenocarcinoma (READ), skin cutaneous melanoma (SKCM), thymoma (THYM), uterine corpus endometrial carcinoma (UCEC), uterine carcinosarcoma (UCS), and uveal Melanoma (UVM). Patients without definitive information of age or race were excluded. The Human methylation450 BeadChip datasets (level three) [@B25] were also downloaded from the Broad GDAC Firehose.

Identification of CpG probes associated with BMI
------------------------------------------------

For adults, BMI was classified according to World Health Organization (WHO) definitions as underweight (BMI \< 18.5), normal weight (18.5 ≤ BMI \< 25), overweight (25 ≤ BMI \< 30), and obese (BMI ≥ 30). In the initial analysis, BMI was used as a categorical variable by dividing the samples into two groups: control BMI subjects (BMI \< 25) and high BMI subjects (25 ≥ BMI). Since the four clinical indicators, including age, gender, race and tissue source site, were all provided in the 15 cancers, and three (age, gender and race) of them had been reported to be associated with BMI and DNA methylation [@B26]-[@B29], we included the four variables into linear models. After adjusting for age, gender, race, and tissue source site, differentially methylated CpG probes between two groups were identified using the linear models for microarray data (limma) package (default), which uses linear models to assess differential methylation, whereby information is shared across probes [@B30]. Differentially methylated CpG sites (DMSs) were identified if the resulting adjusted *P*-value was \< 0.05. The Benjamini-Hochberg method [@B31] was used to adjust the *P*-values and ensure that the*False Discovery Rate (FDR)* was \< 0.05. In the second analysis, BMI was not normally distributed in any cancers and therefore was transformed by rank normalization, which was performed using the rntransform function in the R GenABEL package [@B32]. The Lillie test in nortest package, a modification of the Kolmogorov-Smirnov test, was used to determine whether the data were normally distributed. Multivariable linear regression of normalize-transformed BMI with methylation level at each CpG probe was adjusted for gender, age, race, and tissue source site.

Pathway enrichment analysis
---------------------------

To evaluate the functional relevance of DMSs, a The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis for genes involved in DMSs was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) software [@B33]. The significant enrichment pathways were identified with *P* \< 0.05.

Statistical analysis
--------------------

Statistical analyses were performed using the R software. The survival difference between patient groups was analyzed using the Kaplan-Meier and log-rank test function in survival package. The methylation level was compared between two groups by the Wilcoxon rank test. Over- or under-representation of the CpGs were determined using the chi-square test.*P* values less than 0.05 were considered statistically significant.

Results
=======

The characteristics of the TCGA samples analyzed
------------------------------------------------

To characterize the specific genome-wide DNA methylation profile that is associated with BMI in cancers, we chose 15 publically available cancer datasets from TCGA (Table [1](#T1){ref-type="table"} and Table [S1](#SM0){ref-type="supplementary-material"}). Totally, there are 2415 samples including 883 control BMI samples and 1532 high BMI samples. The average age ranged from 48.4 to 69.6 years old, and the average BMI ranged from 22.6 to 34.4 kg/m^2^. After adjusting for age, race, gender, and tissue source site, we firstly treated BMI as a categorical measure, and performed DMSs analyses between high and control BMIs for each cancer through limma package. Secondly, we treated BMI as a continuous measure, and identified BMI-associated methylated sites (BMSs) using the multivariable linear regression models (Fig. [1](#F1){ref-type="fig"}).

Genome-wide methylation differences in high and control BMI
-----------------------------------------------------------

High BMI has an increased risk for cancers [@B34]. To gain insight into the association between high BMI and DNA methylation, we used 25 kg/m^2^ as a cutoff threshold to divide high BMI and control cases (Table [1](#T1){ref-type="table"}). We separately examined DNA methylation levels between the two groups across the 15 types of cancers. In COAD, the average global DNA methylation levels in high BMI cases (β value = 0.46) were significantly lower than the control cases (β value = 0.47) (*P* = 0.0024). None of other cancers displayed a statistical significance (Fig. [2](#F2){ref-type="fig"}a). Using limma method and a *FDR* value of \< 0.05 as the significance cut-off value for downstream analyses, we identified 3, 1169, and 394 DMSs in CHOL, COAD (Table [S2](#SM0){ref-type="supplementary-material"}), and UCEC (Table [S3](#SM0){ref-type="supplementary-material"}), respectively. There were no DMSs in the other 12 cancers. 3 DMSs in CHOL included cg26987376 that was located at an intergenic region, cg21515384 that was located at 200 bp upstream of the transcription start site (TSS200) of the 3-oxoacid CoA-transferase 1 (OXCT1), and cg02725055 that was located at 1500 bp upstream of the transcriptional start site (TSS1500) of the transcription factor 4 (TCF4). Furthermore, OXCT1 plays important roles in ketone and fatty acid metabolism [@B35]. TCF4 (also known as TCF7L2) is also identified to be a possible determinant of type 2 diabetes mellitus and is a transcription factor of the Wnt signaling pathway, which also plays a crucial role in insulin secretion and proglucagon gene expression [@B36],[@B37].

Among the 1169 DMSs identified in COAD, 1168 DMSs exhibited low methylation levels, and a single DMS exhibited high methylation level in patients with high BMIs (Fig. [2](#F2){ref-type="fig"}b). Compared to all of the analyzed sites, the DMSs were underrepresented in the promoter regions, including the TSS1500, TSS200, 5\' untranslated regions (5\' UTR), and 1^st^ exons, but were overrepresented in the gene body and intergenic regions (Fig. [2](#F2){ref-type="fig"}c). Regarding the CpG context, the 1169 DMSs were significantly overrepresented in the CpG islands and DNA regions within 2 kb of the CpG islands (North Shore and South Shore). Additionally, the genomic regions outside the CpG islands and their 2 kb flanking regions were underrepresented. The 394 DMSs identified in samples of high BMI in UCEC consisted of 128 hypomethylated CpGs and 266 hypermethylated CpGs. These DMSs were significantly overrepresented in the gene body regions and underrepresented in the TSS200 and 1^st^ exons. Regarding the CpG context, the DNA regions 2 kb outside of the CpG islands were overrepresented and the North Shore and CpG island regions were observed to be underrepresented (Fig. [2](#F2){ref-type="fig"}c), suggesting that altered methylated regions for high BMI are clearly tumor- or tissue-specific.

Biological pathways analysis
----------------------------

To understand the functions of DMSs-containing genes, we performed a functional enrichment analysis using the DAVID software [@B33]. In COAD, 1168 DMSs corresponded to 449 unique genes. KEGG pathway analysis provided significant enrichment in 20 pathways (*P* \< 0.05), including numerous biological processes pertinent to cancer, such as the phosphatidylinositol 3-kinase (PI3K)/Akt and hippo signaling pathways (Fig. [3](#F3){ref-type="fig"}a). Interestingly, type II diabetes mellitus which has been reported to be associated with an excess risk of colorectal cancer [@B38], was also included. Tenascin XB, encoding a member of the tenascin family of extracellular matrix (ECM) glycoproteins [@B39], had 23 CpGs with high methylation and was involved in pathways of PI3K-Akt signaling, focal adhesion, and ECM-receptor interaction. Collagen type genes of the three pathways were also subject to methylation in certain CpGs. It is clear that the ECM plays an important role in adipocyte development and function and as such in lipid metabolism, weight regulation, and obesity [@B39]. 116 DMSs enriched in pathways mostly located at the gene body regions of their genes (Table [S4](#SM0){ref-type="supplementary-material"}). We did not identify any significant correlation between these DMSs and their genes in COAD, probably due to that there were 19 overlapping samples between transcriptome and methylome. In UCEC, 394 DMSs corresponded to 253 unique genes, which were involved in focal adhesion, rap 1 signaling pathway, bladder cancer, platelet activation, GnRH signaling pathway, estrogen signaling pathway, proteoglycans in cancer, and endocytosis (*P* \< 0.05) (Fig. [3](#F3){ref-type="fig"}b). Nearly all of these pathways included the epidermal growth factor receptor (EGFR), SRC proto-oncogene, and non-receptor tyrosine kinase, were reported to be drivers of tumorigenesis [@B40],[@B41]. 31 DMSs enriched in pathways mostly located at the gene body regions of their genes (Table [S5](#SM0){ref-type="supplementary-material"}). Among them, 4 DMSs (cg01222719, cg17307474, cg22187246, cg11209289) in gene body regions and 4 DMSs (cg00130530, cg23410129, cg12726213, cg26033529) in promoter regions, were negatively correlated with their corresponding genes (Table [S5](#SM0){ref-type="supplementary-material"}).

Epigenome-wide association study through multivariable linear regression model
------------------------------------------------------------------------------

Next, to investigate whether or not there was a correlation between BMI and DNA methylation in cancers, BMI was used as a continuous measure, and EWASs were performed between CpG sites and BMI using *FDR* \< 0.05 as the cutoff threshold. We identified 1 BMS in CHOL and COAD, respectively, whereas we found 113 BMSs in UCEC (Table [S6](#SM0){ref-type="supplementary-material"}). However, we were unable to identify any significant BMSs in the other 12 cancers that were investigated. The identified BMSs included cg04545963 (β = 0.680, *FDR* = 0.024) located in NF-κB inhibitor alpha (NFKBIA) in CHOL and cg15542880 (β = -0.082, *FDR* = 0.020) located in dual serine/threonine and tyrosine protein kinase (DSTYK) in COAD. Moreover, the identified 113 BMSs in UCEC were annotated to 84 unique genes, and approximately 32% of the BMSs showed a positive correlation to BMI (Table [S6](#SM0){ref-type="supplementary-material"}). The genomic location revealed that 113 BMSs were distributed among 19 chromosomes except for chromosomes 9, 14, and 20 (Fig. [4](#F4){ref-type="fig"}). Some BMSs were located at genes involved with metabolically relevant events. For example, UDP glucuronosyltransferase family 2 member B15 (UGT2B15) was known as a member of the UDP-glucuronosyltransferases superfamily catalyzing the conjugation of various lipid-soluble endogenous substances and xenobiotics with the glucuronic acid moiety UDP-glucuronic acid [@B42]. SRY-box 6 (SOX6), a transcription factor, has been linked to the regulation of the expressions of key adipogenic regulators as well as synergy with epigenetic pathways involving mesoderm-specific transcript genes that are associated with adipocyte size [@B43]. Meanwhile, a SNP in SOX6 gene, rs297325, located 0.22 Mb downstream of cg21992400 (β = -0.088, *FDR* \< 0.05), has been identified to associate with the risk of both BMI and endometrial cancer [@B12]. Among the 84 genes, tumor-related genes were also found, such as T-box 2 [@B44], discoidin domain receptor tyrosine kinase 1 [@B45], and lysine acetyltransferase 6A [@B46]. These results further supported the findings that BMI is associated with DNA methylation profiles in CHOL, COAD, and UCEC.

BMSs in UCEC implicated to tumor progression and patient survival
-----------------------------------------------------------------

Using the more stringent Bonferroni correction for multiple testing (*Bonferroni*-corrected *P* \< 0.05) in the analyses of multivariable linear regression models, cg04545963 in CHOL and cg15542880 in COAD were still significantly associated with BMI. However, in UCEC, the number of significant BMSs was markedly reduced, and only 4 BMSs remained, including cg12645852 (β = -0.107, *Bonferroni*-corrected *P* = 5.85E-04) located in an intergenic region, cg09621472 (β = -0.107, *Bonferroni*-corrected *P* = 0.018) located in NatE catalytic subunit of N (alpha)-acetyltransferase 50 (NAA50), cg27131667 *(*β = -0.198, *Bonferroni*-corrected *P* = 0.028) located in spastic paraplegia 7 (SPG7), and cg14044785 (β = -0.116, *Bonferroni*-corrected *P* = 0.041) located in thyroid adenoma associated (THADA). Of these 4 BMSs, cg12645852, cg09621472, and cg14044785 in patients with high BMI in UCEC had significant hypomethylation when compared to controls.

BMI is a prognostic factor in patients with cancer. Bladder cancer and colorectal cancer show lower mortality in patients with higher BMI values [@B47]. However, the increase of BMI at an older age is associated with a lower overall survival time in patients with pancreatic cancer [@B48]. To explore whether BMS can also predict tumor survival outcome, based on these stringent BMSs, we therefore respectively categorized the study cases into low and high levels according to the median of methylation levels of these 6 BMSs and subsequently performed Kaplan-Meier and Log-rank test. With regards to methylation status, cg04545963 in CHOL, cg15542880 in COAD, and cg12645852 in UCEC did not significantly affect the patient survival rates (Fig. [5](#F5){ref-type="fig"}a). For cg09621472, cg27131667, cg14044785, patients with UCEC with low methylated levels had improved survival rates when compared with those who had high methylated levels (*P* = 0.0008, 0.0248, 0.0109, respectively, Fig. [5](#F5){ref-type="fig"}a), suggesting that cg09621472, cg27131667, and cg14044785 could be used as potential biomarkers for predicting survival outcomes of patients with UCEC.

Furthermore, analyses were performed to investigate whether these BMSs had implications in tumor initiation and progression. The methylation status of cg04545963 was not significantly associated with the initiation and grade of CHOL, and neither was cg15542880 in COAD (Fig. [5](#F5){ref-type="fig"}b). We found that, in adjacent tissue, the methylation levels of cg12645852 and cg27131667 were significantly higher than tumor tissue of the early stages (grade 1) from UCEC. However, for cg09621472, cg27131667, and cg14044785, the methylation levels in adjacent tissues were lower than those of tumor tissues (Fig. [5](#F5){ref-type="fig"}b). Interestingly, with advancing tumor grade, the methylation levels of the 4 BMSs in UCEC significantly increased and displayed the most notable increase from grade 2 to grade 3 (all *P* \< 0.0001, the different β values between the two grades are 0.1598, 0.2135, 0.0883, 0.1447, respectively). Furthermore, their high methylation levels were also associated with other advanced clinical tumor parameters, including tumor invasion percentage, clinical stage, and histologic diagnosis type (Table [S7](#SM0){ref-type="supplementary-material"}). The dataset of GSE67116 [@B49] from the GEO database showed higher methylation levels of cg09621472 (*P \<* 0.001) and cg27131667 (*P* = 0.014) in 33 patients with endometrial metastasis cancer relative to 53 patients with endometrial primary cancer. These data suggested that cg12645852, cg09621472, cg27131667, and cg14044785 may be associated with the effect of BMI on UCEC advancement.

Discussions
===========

In this study, we characterized the genome-wide DNA methylation profiles associated with BMI in 15 cancer types by modeling BMI first as a categorical variable and then as a continuous variable. The two analyses consistently showed that the dynamic features of DNA methylation in the three known obesity-related cancers (CHOL, COAD, and UCEC) [@B50],[@B51] associated with BMI, but not in the other 12 major cancers.

The observed hypomethylation patterns in COAD with high BMI is predominant, indicating that high BMI cases with COAD may regulate gene expression through the attenuation of DNA methylation. These genes containing DMSs play roles in the pathogenesis of colorectal cancer (e.g. DCC netrin 1 receptor; netrin 1; Wnt family member 3A; Wnt family member 5A; receptor tyrosine kinase like orphan receptor 2; RAR related orphan receptor A) [@B52]-[@B57]. Most genes with DMSs enrichment were in the PI3K-AKT signaling pathway, an intercellular signaling pathway responsible for carcinogenesis and metastasis of many cancers [@B58]. This finding is consistent with a previous report showing that the PI3K-AKT signaling pathway links obesity risk factors and colon carcinogenesis processes [@B59]. In obesity cases, increased levels of blood insulin, insulin-like growth factor I, leptin, tumor necrosis factor, and interleukin 6, and decreased levels of adiponectin activate the PI3K-AKT signal pathway, further activating downstream signals for cell survival, cell growth and cell cycle, and ultimately resulting in cancer development. Alterations in DNA methylation also respond to adiposity [@B3], therefore, in COAD, high BMI inhibits methylation of PI3K-AKT signaling pathway genes, which in turn may activate the pathway and the development of COAD. Another noteworthy pathway is that for type II diabetes. Adipose tissue of obesity cases releases various factors, such as non-esterified fatty acids and pro-inflammatory cytokines, which could contribute to development of insulin resistance and perturb β-cell function, thus resulting in type II diabetes [@B2]. This disease plays an important role in the pathogenesis of colon adenocarcinoma. Moreover, epidemiologic studies were directed at providing a consistent association and several shared genetic factors between type II diabetes and subsequent risk of colon cancer [@B38],[@B60],[@B61]. We identified, in patients with COAD and high BMI, significant hypomethylation of type II diabetes pathway genes, thus supporting the possibility that an alteration in this pathway may result in the induction of DNA methylation, and that a high BMI may have an important role in some of the downstream effects of COAD development. Even though the other 18 biological pathways in COAD linking obesity to cancer have not been reported, these pathways allow us to examine whether DNA methylation alterations due to high BMI have effects on colon cancer, particularly in case of cancer-related pathways such as the Hippo signaling pathway and cAMP signaling pathway and in ECM-receptor interaction. High BMI cases in UCEC also present methylation differences in comparison with controls. Some DMSs were located at genes involved in the development of UCEC (e.g. EGFR; kinase suppressor of ras 1; metastasis associated 1; syndecan 1; secreted protein acidic and cysteine rich) [@B62]-[@B66]. Increased platelet activity is mainly related to reactive oxygen species and inflammation adipokines as well as a reduced sensitivity to insulin [@B67]. Obesity drives adipose inflammation, leading to induction of aromatase and increased estrogen signaling in adipose depots [@B68]. These results indicated that high BMI may contributes to modulation of two pathways involved in platelet activation and estrogen signaling as a result of DNA methylation in UCEC. These pathways could provide guidance for further understanding the effects of high BMI on the development of cancer.

When BMI was used as a continuous measure in the EWAS with a strict *Bonferroni* correction (*P* \< 0.05), methylation alterations were identified in the genes including NFKBIA, DSTYK, NAA50, SPG7, and THADA. These genes are highly associated with human disease susceptibility [@B69]-[@B81], but associations of DNA methylation among them have not been reported. Additionally, BMI-associated CpGs located in NAA50, SPG7, and THADA among UCEC tumor tissues are significantly associated with the survival time and tumor progression of this cancer, indicating that BMI may encourage the role of tumor mechanism through controlling DNA methylation. Intensive epigenetic studies have demonstrated a causal relationship between high BMI or obesity and altered epigenetic regulation in a great deal of metabolically important genes or regions [@B3],[@B19],[@B20],[@B82]. Although results of this study reveal that there are no major changes in metabolic processes, the discordance may be interpreted by tissue heterogeneity and tissue-specific patterns of DNA methylation. This deduction is consistent with previous reports showing that DNA methylation in HIF3A was associated with BMI in white blood cells and adipose tissue, but not in breast tumor tissue [@B20],[@B23],[@B83]. Furthermore, most studies have previously focused on blood or adipose tissue that are metabolically active; however, this cannot be used to reflect epigenetic patterns of other tissues. In another study using breast tumor tissue, obesity was shown to influence the methylation of some cancer-relevant genes and pathways involved in carcinogenesis [@B23]. The use of human primary tumor tissues in our study from 15 tumor types exclusive of the breast cancer significantly revealed new information. Thus, we demonstrated that high BMI may induce metabolic perturbations, leading to alterations in DNA methylation in cancer development-related and obesity-induced pathways in primary tumor tissues of CHOL, COAD, and UCEC.

Excluding the overweight group, we also analyzed the methylation differences between obese and control BMI of cancer patients (Table [S8](#SM0){ref-type="supplementary-material"}). The result suggested that the cutoff values of BMI influence the methylation differences. Removal of the overweight group resulted in detections of DMSs (Table [S8](#SM0){ref-type="supplementary-material"}). TCGA dataset is heterogeneous and lack of unified information parameters (e.g., the history of smoking and drinking, etc.) in the subjects examined. This may be the reason why BMI-associated methylation patterns were not determined in the other 12 tumors. We further analyzed regression association analysis between BMI and DNA methylation in adjacent tissues from CHOL, COAD, UCEC, but failed to identify any significant BMSs. Further investigations may be needed when more samples become available in the future. In addition, DMS outcomes might be inadequately estimated in gene expression because the number of the overlapping samples between transcriptome and methylome was low. BMI grouping is possible and it can minimize the possible bias due to an underestimation of weight. However, BMI grouping obscures detection of possible correlations at within-group level. Instead, the BMI is a continuous variable in TCGA dataset, allowing the identifications of significant CpGs with the considerations of common confounders (age, gender, race, tissue source site) via multiple linear regression. With larger datasets in the future, improvement may be made on specifying how independent variables are entered into a given linear regression modeling. More sophisticated models may be deployed to improve the analytical power too, because possibilities of lacking normal and/or random distributions of independent variables, as well as the linear validity between independent variables and BMI could reduce the statistical power of the linear regression model. Therefore, these BMI-associated methylation pattern still need to be validated by a large-scale clinical samples.

Collectively, we systemically analyzed the association of BMI with genomic DNA methylation in tumor tissues. This study supports the view that changes in DNA methylation represent an intermediate step between the BMI and CHOL, COAD, or UCEC, which may in turn provide information for guiding treatment options for patients with CHOL, COAD, and UCEC with high BMIs.
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![Analysis of differences in genomic DNA methylation levels in cases of high body mass index (BMI) and controls. (A) The differences in genomic DNA methylation levels in 15 cancer types. (B) Volcano plot showing the distribution of CpG sites from the site-level test assessed by methylation differences and*FDR* values. CpGs in blue indicate a *FDR* \< 0.05. (C) Significant differences in the genomic distributions of the differentially methylated CpGs regarding the CpG context and the gene region, compared with all analyzed sites on the Infinium HumanMethylation450 BeadChip, by chi-square test. (\* *p* \< 0.05; \*\* *p* \< 0.01; \*\*\* *p* \< 0.001; N_Shelf, North Shelf; S_Shelf, South Shelf; N_Shore, North Shore; S\_ Shore, South Shore).](jcav09p2532g002){#F2}

![Bar graph showing significant KEGG pathways of genes involving with differentially methylated CpGs. (A) Biological pathways in COAD; (B) Biological pathways in UCEC.](jcav09p2532g003){#F3}

![Circos plot of the epigenome-wide association of DNA methylation in UCEC with body mass index (BMI). Results are presented as CpG-specific association test results (-log~10~ (*FDR*)) ordered by genomic position. Green symbols, CpGs positively associated with BMI; Red symbols, CpGs negatively associated with BMI; Chromosome numbers are shown on the inner ring. Tick marks on the outer ring identify the genomic locis reaching epigenome-wide significance. The genes located by the 113 locis are listed around the circos plot.](jcav09p2532g004){#F4}

![Analysis of body mass index (BMI)-associated CpGs during the survival initiation, stage, and progression of CHOL, COAD, and UCEC. (A) Kaplan-Meier survival analysis. The patients were divided into low and high groups using the median cutoff value of DNA methylated levels for the 6 BMI-associated CpGs, respectively. HR, hazard ratio. (B) The methylation levels of BMI-associated CpGs in the initiation and progression of the three cancers (\* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001, no represents statistically insignificant).](jcav09p2532g005){#F5}

###### 

The characteristics of eligible TCGA samples

  -------------------------------------------------------------------------------------------------------------------
  Cancer types   Age (years)   Races               Gender (% male)   BMI (kg/m^2^)   No. Control BMI   No. High BMI
  -------------- ------------- ------------------- ----------------- --------------- ----------------- --------------
  BLCA           67.8 (10.5)   a(284); b(43);\     75%               27.1 (6.3)      142               203
                               c(18)                                                                   

  CESC           48.4 (13.5)   a(189);b(19);\      0%                28.4 (7.8)      89                150
                               c(23); d(7); e(1)                                                       

  CHOL           63.4 (12.8)   a(30);b(3);\        45.7%             28.0 (5.3)      10                25
                               c(2)                                                                    

  COAD           64.4 (13.1)   a(164);b(8);\       54%               29.4 (17.4)     75                149
                               c(51);d(1)                                                              

  DLBC           56.3 (13.9)   a(29);b(18);\       45.8%             25.9 (5.9)      25                23
                               c(1)                                                                    

  ESCC           58.7 (10.5)   a(41);b(44);\       85.2%             22.6 (3.4)      70                18
                               c(3)                                                                    

  EAC            66.6 (11.8)   a(66);b(1)          88.1%             28.6 (6.4)      16                51

  KIRP           61.7 (12.0)   a(152);b(4);\       74.5%             32.1 (32.8)     47                149
                               c(39);d(1)                                                              

  LIHC           59.1 (12.9)   a(159);b(157)\      68.6%             26.1 (8.5)      175               156
                               c(14);d(1)                                                              

  READ           61.1 (11.5)   a(62);c(5)          59.7%             27.2 (5.8)      18                49

  SKCM           59.4 (15.3)   a(227);b(11);\      59.0%             28.0 (6.1)      79                160
                               c(1)                                                                    

  THYM           58.8 (12.9)   a(83);b(12);\       52.0%             27.2 (6.03)     38                60
                               c(3)                                                                    

  UCEC           64.0 (11.0)   a(275);b(87);\      0%                34.4 (13.0)     65                314
                               c(8);d(2);e(7)                                                          

  UCS            69.6 (9.22)   a(40);b(3);\        0%                29.6 (9.03)     17                34
                               c(8)                                                                    

  UVM            61.3 (13.7)   a(53)               52.8%             28.7 (8.9)      17                36
  -------------------------------------------------------------------------------------------------------------------

**Abbreviations:** a, White; b, Asian; c, Black or African American; d, American indian or Alaska native; e, Native hawaiian or other pacific islander. For age and BMI, data are mean (Standard Error). For race, data are race names (number).
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